Antares Pharma Inc ATRS shares are trading higher Wednesday after the company announced it will be acquired by Halozyme Therapeutics Inc HALO for $5.60 per share in cash, valuing Antares at approximately $960 million.
The transaction was unanimously approved by both the Halozyme and Antares boards of directors and is expected to be immediately accretive to Halozyme's 2022 revenue and non-GAAP earnings. Halozyme expects the acquisition to accelerate top- and bottom-line growth through 2027.
The business combination aims to create a leading drug delivery and specialty product company. Antares is a specialty pharmaceutical company focused on the development and commercialization of self-administered parenteral pharmaceutical products and technologies.
See Also: Why BriaCell Therapeutics Stock Is Surging Today
ATRS 52-Week Range: $3.11 - $4.63
According to data from Benzinga Pro, the stock was up 49.1% at $5.58 at press time.
Photo: Parentingupstream from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
